The “Big short” of minimally invasive pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. A cost-effectiveness analysis based on randomized trials
HPB · 2026
DOI: 10.1016/j.hpb.2025.10.014 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift HPB, 2026. Verfasst von Claudio Ricci und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Surgery (DIMEC), Alma Mater Studiorum, University of Bologna, Italy. Electronic address: claudio.ricci6@unibo.it. Hauptthemen laut MEDLINE: Pancreaticoduodenectomy, Pancreatic Neoplasms, Robotic Surgical Procedures, Laparoscopy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: The cost-effectiveness of a laparoscopic (LPD) and robotic pancreaticoduodenectomy (RPD), compared with the open approach (OPD), is still under debate. METHODS: A Markov decision model was developed to compare OPD, LPD, and RPD. The healthcare costs and quality-adjusted life years (QALYs) were estimated by calculating the incremental cost-effectiveness ratio (ICER) per QALY gained. A willingness-to-pay (WTP) of $130,049 was assumed as the threshold. A probabilistic sensitivity analysis (PSA) was performed to reflect the uncertainty of various parameters. RESULTS: In the base case scenario, LPD and RPD were associated with increased costs of US $30,047 and US $30,822, respectively, leading to an ICER of US $-3,911,669 and US $-1,164,992 per QALY. When comparing LPD with OPD, three main factors influence the model: OPD costs (68.8 %), LPD costs (27.9 %), and the complication rate after LPD (2.3 %). In comparing RPD with OPD, two main factors affect the model: RPD costs (75.2 %) and OPD costs (23.3 %). PSA analysis confirmed that OPD was the most cost-effective choice in most cases (62.6 %), while RPD and LPD were the most cost-effective procedures in 26.2 % and 11.9 %, respectively. CONCLUSION: The RDP and LPD were not cost-effective. OPD remained the best approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Internal Medicine and Surgery (DIMEC), Alma Mater Studiorum, University of Bologna, Italy. Electronic address: claudio.ricci6@unibo.it.
- Division of Pancreatic Surgery, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, via Albertoni 15- Italia, Italy.
- Department of Internal Medicine and Surgery (DIMEC), Alma Mater Studiorum, University of Bologna, Italy.
- Department of Internal Medicine and Surgery (DIMEC), Alma Mater Studiorum, University of Bologna, Italy; Division of Pancreatic Surgery, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, via Albertoni 15- Italia, Ital…
Zitieren
APA
Ricci, C., Alberici, L., D'Ambra, V., Ingaldi, C., Fichera, M., & Casadei, R. (2026). The “Big short” of minimally invasive pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. A cost-effectiveness analysis based on randomized trials. HPB. https://doi.org/10.1016/j.hpb.2025.10.014
Vancouver
Ricci C, Alberici L, D'Ambra V, Ingaldi C, Fichera M, Casadei R. The “Big short” of minimally invasive pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. A cost-effectiveness analysis based on randomized trials. HPB. 2026. doi:10.1016/j.hpb.2025.10.014
BibTeX
@article{Ricci2026,
author = {Ricci, Claudio and Alberici, Laura and D'Ambra, Vincenzo and Ingaldi, Carlo and Fichera, Marco and Casadei, Riccardo},
title = {The “Big short” of minimally invasive pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. A cost-effectiveness analysis based on randomized trials},
journal = {HPB},
year = {2026},
doi = {10.1016/j.hpb.2025.10.014}
}
EUVIMED